GlassScriptPhysician profile
Amjad A Bukhari
NPI 1972896249
$10,270.07
in general payments reported to CMS, 2019-2025
59 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $267 · 2021: $417 · 2022: $2,203 · 2023: $1,653 · 2024: $2,662 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,574 · Education: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,574.31 |
| Education | $483.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,620.22 | 2019-2025 | Botox, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $911.94 | 2019-2025 | |
| Livanova USA, INC. | $752.78 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $658.05 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Alexion Pharmaceuticals, INC. | $523.22 | 2019-2025 | Ultomiris, Soliris |
| Mdd US Operations, LLC | $506.38 | 2023-2025 | Gocovri, Gocovri |
| Pfizer INC. | $469.63 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $439.66 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Biogen, INC. | $372.44 | 2019-2024 | Vumerity, Skyclarys, Tysabri |
| Argenx US, INC. | $284.87 | 2022-2025 | Vyvgart |
| Biohaven Pharmaceutical Holding Company LTD. | $284.13 | 2022 | |
| Csl Behring | $270.11 | 2019-2023 | Hizentra |
| Lilly USA, LLC | $247.31 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Emd Serono, INC. | $227.97 | 2019-2025 | |
| Allergan, INC. | $217.90 | 2019-2021 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amjad Bukhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.